Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200470293> ?p ?o ?g. }
- W4200470293 endingPage "122" @default.
- W4200470293 startingPage "122" @default.
- W4200470293 abstract "From a complete literature review, we were able to present in this paper what is most current in the treatment with immunotherapy for advanced non-small cell lung cancer (NSCLC). Especially the use of immunotherapy, particularly inhibitors of PD-1 (programmed cell death protein 1), PDL-1 (programmed cell death protein ligand 1), and CTLA-4 (cytotoxic T-lymphocyte antigen 4). Since 2015, these drugs have transformed the treatment of advanced NSCLC lacking driver mutations, evolving from second-line therapy to first-line, with excellent results. The arrival of new checkpoint inhibitors such as cemiplimab and the use of checkpoint inhibitors earlier in the therapy of advanced and metastatic cancers has been making the future prospects for treating NSCLC lacking driver mutations more favorable and optimistic. In addition, for those patients who have low PDL-1 positivity tumors, the combination of cytotoxic chemotherapy, VEGF inhibitor, and immunotherapy have shown an important improvement in global survival and progression free survival regardless the PDL-1 status. We also explored the effectiveness of adding radiotherapy to immunotherapy and the most current results about this combination. One concern that cannot be overlooked is the safety profile of immune checkpoint inhibitors (ICI) and the most common toxicities are described throughout this paper as well as tumor resistance to ICI." @default.
- W4200470293 created "2021-12-31" @default.
- W4200470293 creator A5026030471 @default.
- W4200470293 creator A5038704798 @default.
- W4200470293 creator A5043529311 @default.
- W4200470293 creator A5063372423 @default.
- W4200470293 creator A5068564224 @default.
- W4200470293 creator A5072469576 @default.
- W4200470293 creator A5088902441 @default.
- W4200470293 date "2021-12-28" @default.
- W4200470293 modified "2023-10-06" @default.
- W4200470293 title "Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives" @default.
- W4200470293 cites W1514134885 @default.
- W4200470293 cites W1705538174 @default.
- W4200470293 cites W1893566975 @default.
- W4200470293 cites W1982488143 @default.
- W4200470293 cites W2003984225 @default.
- W4200470293 cites W2032517155 @default.
- W4200470293 cites W2096619429 @default.
- W4200470293 cites W2104347254 @default.
- W4200470293 cites W2117692326 @default.
- W4200470293 cites W2132157071 @default.
- W4200470293 cites W2133668831 @default.
- W4200470293 cites W2145550995 @default.
- W4200470293 cites W2154149901 @default.
- W4200470293 cites W2155464214 @default.
- W4200470293 cites W2156353875 @default.
- W4200470293 cites W2166749501 @default.
- W4200470293 cites W2175964092 @default.
- W4200470293 cites W2198093519 @default.
- W4200470293 cites W2293531514 @default.
- W4200470293 cites W2527905628 @default.
- W4200470293 cites W2567564314 @default.
- W4200470293 cites W2635951006 @default.
- W4200470293 cites W2676895855 @default.
- W4200470293 cites W2753065806 @default.
- W4200470293 cites W2756916963 @default.
- W4200470293 cites W2768429453 @default.
- W4200470293 cites W2788965853 @default.
- W4200470293 cites W2789156026 @default.
- W4200470293 cites W2790549883 @default.
- W4200470293 cites W2790743957 @default.
- W4200470293 cites W2796582438 @default.
- W4200470293 cites W2800160190 @default.
- W4200470293 cites W2805250652 @default.
- W4200470293 cites W2805354595 @default.
- W4200470293 cites W2809501033 @default.
- W4200470293 cites W2892640821 @default.
- W4200470293 cites W2918948206 @default.
- W4200470293 cites W2919091706 @default.
- W4200470293 cites W2925446385 @default.
- W4200470293 cites W2946386783 @default.
- W4200470293 cites W2964471257 @default.
- W4200470293 cites W2967266245 @default.
- W4200470293 cites W2971041600 @default.
- W4200470293 cites W2976744492 @default.
- W4200470293 cites W2978539957 @default.
- W4200470293 cites W2980537150 @default.
- W4200470293 cites W3004475955 @default.
- W4200470293 cites W3015859409 @default.
- W4200470293 cites W3016783954 @default.
- W4200470293 cites W3043699718 @default.
- W4200470293 cites W3092130195 @default.
- W4200470293 cites W3092921002 @default.
- W4200470293 cites W3093501115 @default.
- W4200470293 cites W3093708469 @default.
- W4200470293 cites W3095502396 @default.
- W4200470293 cites W3108472845 @default.
- W4200470293 cites W3108819942 @default.
- W4200470293 cites W3121907365 @default.
- W4200470293 cites W3129022890 @default.
- W4200470293 cites W3129132496 @default.
- W4200470293 cites W3133710376 @default.
- W4200470293 cites W3162040459 @default.
- W4200470293 cites W3199241644 @default.
- W4200470293 cites W4234236664 @default.
- W4200470293 doi "https://doi.org/10.3390/cancers14010122" @default.
- W4200470293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35008287" @default.
- W4200470293 hasPublicationYear "2021" @default.
- W4200470293 type Work @default.
- W4200470293 citedByCount "12" @default.
- W4200470293 countsByYear W42004702932022 @default.
- W4200470293 countsByYear W42004702932023 @default.
- W4200470293 crossrefType "journal-article" @default.
- W4200470293 hasAuthorship W4200470293A5026030471 @default.
- W4200470293 hasAuthorship W4200470293A5038704798 @default.
- W4200470293 hasAuthorship W4200470293A5043529311 @default.
- W4200470293 hasAuthorship W4200470293A5063372423 @default.
- W4200470293 hasAuthorship W4200470293A5068564224 @default.
- W4200470293 hasAuthorship W4200470293A5072469576 @default.
- W4200470293 hasAuthorship W4200470293A5088902441 @default.
- W4200470293 hasBestOaLocation W42004702931 @default.
- W4200470293 hasConcept C121608353 @default.
- W4200470293 hasConcept C126322002 @default.
- W4200470293 hasConcept C143998085 @default.
- W4200470293 hasConcept C154317977 @default.
- W4200470293 hasConcept C202751555 @default.
- W4200470293 hasConcept C203014093 @default.